Please assess the completion status of the following clinical trial:

Trial Title: Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-pubertal boys between 6 and 10 years of age or girls between 6 and 9 years of age.~* Birth length- and/or birth weight-SDS adjusted to gestational age \< -2.0 (Voigt et al. 2002, Voigt et al. 2006 or Lawrence et al. 1989).~* Current height-SDS \< -2.5 (Brandt/Reinken 1992) and parental adjusted height-SDS below -1 (Hermanussen and Cole 2003).~* Growth velocity SDS \< 0 during the last year before inclusion (Brandt/Reinken 1988).~Exclusion Criteria:~* Severe SGA (birth weight or length \< -4 SD) and clinically relevant dysmorphic features.~* Severe pre-maturity (GA \< 32 weeks of gestation).~* Severe perinatal complications like asphyxia, sepsis, necrotizing enterocolitis (NEC), respiratory distress syndrome, if associated with long-term sequelae (like short bowel syndrome, bronchopulmonary dysplasia (BPD), cerebral palsy etc).~* Inability to perform one- or two leg jumps from a standing position.~* Prior GH treatment.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): Somatropin for 12 months
- Control Group (Type: OTHER): In the first 6 months no intervention, afterwards Somatropin for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).